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Abstract
We explored the possibility to target Ewing’s sarcoma family of tumors (ESFT) by redirecting T cells. To this aim, we
considered NKG2D-ligands (NKG2D-Ls) as possible target antigens. Detailed analysis of the expression of MICA, MICB, ULBP-
1, -2, and -3 in fourteen ESFT cell lines revealed consistent expression of at least one NKG2D-L. Thus, for redirecting T cells,
we fused a CD3f/CD28-derived signaling domain to the ectodomain of NKG2D, however, opposite transmembrane
orientation of this signaling domain and NKG2D required inverse orientation fusion of either of them. We hypothesized that
the particularly located C-terminus of the NKG2D ectodomain should allow reengineering of the membrane anchoring from
a native N-terminal to an artificial C-terminal linkage. Indeed, the resulting chimeric NKG2D receptor (chNKG2D) was
functional and efficiently mediated ESFT cell death triggered by activated T cells. Notably, ESFT cells with even low NKG2D-L
expression were killed by CD8
pos and also CD4
pos cells. Both, mRNA transfection and lentiviral transduction resulted in high
level surface expression of chNKG2D. However, upon target-cell recognition receptor surface levels were maintained by
tranfected RNA only during the first couple of hours after transfection. Later, target-cell contact resulted in strong and
irreversible receptor down-modulation, whereas lentivirally mediated expression of chNKG2D remained constant under
these conditions. Together, our study defines NKG2D-Ls as targets for a CAR-mediated T cell based immunotherapy of ESFT.
A comparison of two different methods of gene transfer reveals strong differences in the susceptibility to ligand-induced
receptor down-modulation with possible implications for the applicability of RNA transfection.
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Introduction
A subgroup of patients with Ewing’s sarcoma family of tumors
(ESFT) is still threatened by a poor long term prognosis. Despite
modern multimodal therapy (chemotherapy, radiation, and
surgery) ESFT relapse in about 30% of patients with localized
disease. Long-term survival of those who relapsed and of patients
with metastatic disease at diagnosis is currently below 30% [1–3].
Therefore, new treatment options are needed.
Tumors cells frequently up-regulate ‘‘stress’’ induced ligands
recognized by the NK cell activating receptors DNAM-1 (CD226)
and NKG2D (CD314), whose ligands have been found recently
also on ESFT cells [4]. Therefore, the infusion of NK cells has
emerged as a promising new treatment strategy for malignant
tumors in general and has been also suggested for the treatment of
ESFT [4,5]. NK cells due to their innate specificity allow tumor
targeting without extensive ex vivo modification, and have not been
reported to cause auto- or allo-immune side-effects following
transfusion even across MHC barriers [6,7]. CD8
pos T cells, on
the other hand, are characterized by the capacity to differentiate
into effector cells or long term memory cells, and have been
adopted in the past with a broad range of new antigenic
specificities by receptor transfer (for review see [8]).
NKG2D recognizes several ligands (MICA, MICB, ULBP-1 to
ULBP-6) with only restricted expression in normal tissues [9,10].
Utilizing this receptor for redirecting T cells, Sentman and co-
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chimeric T cell antigen receptor (CAR) and demonstrated its
efficacy against a variety of malignant cells in vivo and in vitro [11–
14]. We wanted to further develop this approach for targeting
ESFT and decided to construct a similar NKG2D-based CAR,
but - based on the known 3D-structure of NKG2D - focused on
reengineering the extra-cellular domain of NKG2D to allow its
fusion in type I membrane protein orientation to the signaling
domain of a second generation CAR, which contains also CD28
for enhanced signal transduction [8,15,16]. Here we report that
this new chNKG2D successfully allowed us to establish a T cell
based approach for efficient ESFT cell elimination.
For expression of this chimeric receptor we compared two
different methods of gene transfer, namely mRNA transfection
and lentiviral transduction, since both methods are currently
considered for clinical application. Lentiviral mediated gene
transfer mediates stable transgene expression and therefore is
attractive, because the clinical effectiveness of adoptive tumor
therapy has been correlated with the persistence of transferred
cells [17]. On the other hand, the transient nature of receptor
expression following mRNA transfection might be an advantage
under the aspects of safety and other regulatory issues. Although
mRNA transfection thus has important benefits, we asked how
such transient expression influences receptor stability following
target cell recognition.
Materials and Methods
Ethics Statement
Written informed consent was obtained from all healthy
voluntary donors involved in the study (commissioned by the
local ethic committee of the Friedrich-Alexander Universita ¨t
Erlangen-Nu ¨rnberg, Ethics proposal 2247, 10.07.2000). All data
were analyzed anonymously.
Cells
Primary human mononuclear cells (MNCs) were obtained from
blood of healthy voluntary donors (commissioned by the local
ethic committees) by density gradient centrifugation using
endotoxin-free Ficoll-Paque-PLUSH (Amersham Pharmacia Bio-
tech AB, Uppsala, Sweden). CD8
pos and CD4
pos T cells were
isolated from MNCs by negative magnetic selection using
microbeads (Miltenyi Biotec, Bergisch-Gladbach, Germany). T
cells were cultured in R10-IL2 medium consisting of RPMI 1640
supplemented with 10% FBS and 100 U/ml IL-2 (Millipore,
Billerica, MA). 293T cells and the myeloid cell lines MONO-
MAC-6, U-937, HL-60, NB-4, OCI-AML5, MV4-11, KG-1a,
and THP-1 were obtained from the German Resource Center for
Biologic Material (DSMZ, Braunschweig, Germany), the glioblas-
toma cell line U-373 was obtained from ATCC. The ESFT cell
lines STA-ET-1, -2, -3, -6, -8.2, -10, -11, ER-ESFT-1 were
generated in house [18,19], CADO-ES1, TC-71, WE-68, VH-64
were provided by Frans van Valen [20]. All ESFT cell lines were
maintained in culture dishes, which were pre-coated for 2 hours at
RT with a 0.1% gelatin solution in PBS. Murine cell lines stably,
expressing either human ULBP2 or MICA, were generated by
transduction of Ba/F3 pre-B cells with a pMX-pie based retroviral
expression vector [21]. All cell lines were maintained in RPMI
1640 supplemented with 10% FBS and IFN-c when indicated.
Generation of chNKG2D
The extracellular portion of human NKG2D (aa82–216) was
amplified by PCR from a plasmid containing the NKG2D cDNA
sequence by using the primers 59-cgaatagtccatggaagcttagccac-
catgccgctgctgctactgctgcccctgctgtgggcaggggccctggctatgggtacctcta-
gattattcaaccaagaagttcaaattccc-39 containing a Kozak-sequence
(bold), CD33 signal peptide sequence (underlined), restriction sites
(italic) of NcoI and HindIII downstream; 59-gatgtcacggatccccgc-
caccgcccgatccaccacctcctgaca-cagtcctttgcatgcagatg-39 with a
BamHI-site (bold) and the Gly4Ser-Gly4Asp-linker (underlined).
The PCR product was cloned by NcoI6BamHI restriction into the
retroviral vector pBullet 607 containing the IgG1-Fc/CD28/
CD3f backbone [22]. For in vitro transcription, the NKG2D
portion was recloned from the pB607/NKG2D vector into the
pGEM4Z-CEA vector, also containing the IgG1-Fc/CD28/CD3f
backbone, by NcoI6BamHI restriction. The NKG2D portion was
additionally recloned from the pB607/NKG2D vector into a
derivate of the vector pST1 (provided by U. Sahin) for
transcription of ‘‘RNA #2’’. The scFv-portion of a Cytomegalo-
virus glycoprotein gB (CMV-gB)-specific IgG1-Fc/CD28/CD3f-
CAR-construct [23] was replaced by HindIII6BamHI restriction.
After recloning, the polyA tail was found to be shortened from 120
to approximately 100 A nucleotides as estimated by Eco53KI
restriction. This vector was linearized for in vitro transcription with
LguI to produce a polyA-tail devoid of non-A nucleotides. For
lentiviral expression NKG2D/IgG1-Fc/CD28/CD3f was excised
from pB607/NKG2D by HindIII6BspEI restriction and cloned
into the PmeI site of the lentiviral plasmid pWPI (D. Trono,
Geneva).
In vitro transcription and RNA-electroporation
In vitro transcription and electroporation was performed as
previously described [24]. Briefly, in vitro transcription was
performed with linearized pGEM4Z-NKG2D or pST1-NKG2D
using the mMESSAGE-mMACHINE-T7 Ultra kit (Applied
Biosystems/Ambion) followed by polyadenylation. The vector
pST1 was developed by Holtkamp et al. [25] to allow in vitro
transcription of a more stable mRNA and the kit used for in vitro
transcription was optimized for a more efficient translation
initiation by using the modified anti-reverse cap analog (ARCA,
7-methyl(39-O-methyl)GpppG)m7G(59)ppp(59)G). RNA from a
cognate CMV-gH-specific IgG1-Fc/CD28/CD3f-CAR (Goetz
G., unpublished) served as control. Electroporation was performed
with 10 mg RNA/100 ml Opti-MEM containing #6610
6 CD8
pos
or CD4
pos T cells either immediately after isolation or 12 days
after activation with an anti-CD3-antibody (clone OKT3). Anti-
CD3-activation was performed by plating 0.2610
6 T cells/ml on
wells pre-coated with 10 mg/ml of anti-CD3-antibody in R10-IL2
medium. After two days the cells were transferred to fresh wells
without anti-CD3-antibody. Half of the medium was replaced
twice a week. Electroporated T cells were further cultured in R10-
IL2 medium and used for functional analysis one day after RNA
transfection.
Production of lentivirus and transduction of T cells
293T cells were seeded in 75 cm
2 flasks and transfected using
Lipofectamine 2000 (Invitrogen Corporation, Bethesda, MD)
according to manufacturer’s instructions. The pWPI vector
plasmid containing the chNKG2D was cotransfected together
with psPAX2 (packaging) and pMD2.G (VSV-G, envelope) in a
ratio of 4:3:1 (total 15 mg plasmid) with 12.5 ml Lipofectamine
2000 per flask. The supernatants were collected 48 hours after
transfection by centrifugation (10 min, 2000 rpm) to remove cell
debris, and were stored at 280uC until further usage. Prior to
transduction primary human cells were activated over night by
2.4 mg/ml PHA in R10-IL2 medium. Transduction was per-
formed by spinoculation of 0.5–1610
6 cells with 0.5 ml of virus
containing supernatant (minimum 0.5 mg p24; quantified by
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15006g for 4 hours at 33uC. After an additional incubation over
night at 37uC the cells were washed twice and further maintained
in R10-IL2 medium. For enrichment of chNKG2D
pos cells
irradiated ULBP2 expressing murine Ba/F3 cells were added
1:1 in weekly intervals. Control T cells transduced with a pWPI
vector containing a cognate CMV-gB-specific CAR [23] were
enriched by co-culture with irradiated murine IIA1.6 cells stably
expressing CD64 (provided by Jan van de Winkel; University
Medical Center Utrecht, The Netherlands). The immunopheno-
type of transduced T cells was controlled by flow cytometry before
functional analysis (data not shown). Only pure CD3
pos TCRa/
b
pos cultures not containing NK cells were used in functional
assays seven to ten days after the last stimulation with ligand
pos
target cells.
Flow cytometry
Human cells were analyzed by anti-CD3 (clone S4.1), anti-CD4
(clone SK3), anti-CD8 (clone SK1), anti-CD56 (clone
NCSM16.2), anti-pan TCR-alpha/beta (clone BMA031), anti-
MHC-class-I (clone Tu ¨149), and appropriately labeled IgG1 and
IgG2b isotype controls. Expression of chNKG2D was detected
either by anti-CD314 (clone 1D11) or via its human IgG1-Fc
portion using biotinylated anti-human-Fc (clone JDC-10) and
streptavidin-PE. NKG2D-Ls were analyzed with anti-MICA
(clone AMO1), anti-MICB (clone BMO2), anti-ULBP1 (clone
AUMO2), anti-ULBP2 (clone BUMO1), anti-ULBP3 (clone
CUMO3) (all from Axxora Life Sciences Inc., San Diego, CA)
and an APC-labeled goat-anti-mouse-IgG used as secondary
antibody.
ELISA
50 000 activated T cells were co-cultured with 100 000 target
cells in 0.5 ml of R10-IL2 medium supplemented with 0.3%
SandoglobulinH (CSL Behring, King of Prussia, PA). Co-culture
with ESFT cells was performed in gelatin coated wells.
Supernatants were harvested after 20 hours and TNF, FasL, and
TRAIL were determined by using ELISA kits from Mabtech,
Diaclone, and BD Biosciences, respectively, according to the
manufacturer’s instructions. The figures show total cytokine levels
without background subtraction.
Cytotoxicity assay
The cytoxic activity was analyzed either by determining target
cell lysis using a non-radioactive Europium (Eu)-based assay or, if
Eu-labeling of target cells was inefficient, by determining apoptosis
induction in target cells by flow cytometry. Europium assay: ESFT
cells were harvested by trypsin/EDTA treatment and labeled with
Eu as previously described [26]. Eu released from 1000 labeled
target cells was determined in the supernatants after 4 hours of co-
culture. Specific lysis was calculated by the formula: %
lysis=(experimental counts minus spontaneous release)6100/
(maximum release minus spontaneous release). Annexin V
apoptosis assay: Target cells were harvested, washed in PBS and
labeled by incubation with 2 mM SNARF-1 carboxylic acid,
acetate succimidyl ester (Invitrogen) in PBS for 15 minutes at
37uC. Labeled cells (5000) were preincubated with 1% Sandoglo-
bulinH for 20 minutes and then co-cultured with effector T cells at
the indicated ratios in 200 ml R10-IL2 medium in a 96 well round
bottom plate. After 5 hours, the cells were harvested by trypsin/
EDTA and then supplemented with 1% FBS, 2 mM CaCl2, and
Annexin V-FITC. The fraction of Annexin V
pos cells of SNARF-
labeled target cells was determined by flow cytometry (measured in
FL4). The percentage of spontaneous Annexin V
pos target cells (in
absence of T cells) was subtracted as unspecific background and
the fraction of ‘‘specific’’ Annexin V
pos targets actually induced by
T cells was calculated by the formula: % Annexin V
pos=(Annxin
V
pos of co-culture minus spontaneous Annexin V
pos)6100/
(100 minus spontaneous Annexin V
pos). The fraction of sponta-
neous Annexin V
pos and maximum possible Annexin V
pos (100%)
cells were corrected by the fraction of actually ligand expressing
cells of the stably transfected cell line Ba/F3 (70–90%).
Statistical analysis
Statistical significance was estimated with the paired two-tailed
Student’s t test (***=P,0.001, **=P,0.01, *=P,0.05,
ns=P.0.05).
Results
Expression of NKG2D-ligands in ESFT
The expression of different NKG2D-Ls has been reported
previously for several ESFT cell lines [4]. Here, we screened 14
ESFT cell lines for the expression of MICA, MICB, and ULBP1,
ULBP2, and ULBP3 by flow cytometry. The results emphasize
that NKG2D-Ls appear to be broadly expressed by ESFT cell
lines, although some (STA-ET-1, -6, -8.2, -10, -11) displayed only
fairly low ligand expression (Fig. 1). Most cell lines expressed
MICA and frequently also ULBP1 and/or ULBP2. MICB was
only weakly expressed in some cell lines and ULBP3 was
consistently absent. From the data we concluded that NKG2D-
Ls might allow targeting of a broad range of ESFT cells.
Construction of the chNKG2D
Existing signaling platforms of CARs are derived from type I
transmembrane proteins with extra-cellular N- and intra-cellular
C-terminus. NKG2D, contrary to most transmembrane proteins,
however, is a type II receptor with inverse orientation. Fusion of
NKG2D with the existing signaling platforms therefore could alter
their configuration and function. To avoid this and to allow future
improvements of signaling we tested the option of constructing a
chNKG2D with type I orientation. The ectodomain of wildtype
NKG2D forms non-covalent homo-dimers and is linked to the
transmembrane domain via a 21 amino acid residues (aa) long
highly flexible anchor (aa75–95). Analyzing the published crystal
structure (Protein Data Bank; accession code 1HYR) revealed that
the C-terminal end of NKG2D protrudes from the globular
ectodomain in close proximity to the entry site of the membrane
anchor (Fig. 2A) [16]. Thus, we hypothesized that the NKG2D
ectodomain could be alternatively anchored via a C-terminal
linkage without disturbing its relative positioning. This should
allow its integration into a CAR composed of a well established
IgG1-Fc/CD28/CD3f signaling platform with type I orientation
[22]. We chose to truncate the NKG2D ectodomain within its
native membrane anchor at aa81 thereby removing the trans-
membrane and intracellular portion of NKG2D and to fuse its C-
terminal end (aa216) via an artificial flexible Gly/Ser-linker to the
N-terminus of the IgG1-Fc/CD28/CD3f molecule. The flexible
upper hinge residues (DKTHT) followed by the hinge core
residues (CPPC) containing the inter-chain disulfide bonds of
IgG1-Fc served as N-terminal acceptor site of the signaling
platform [27]. We calculated that a linker consisting of two Gly/
Ser-repeats (GGGGSGGGGD; last serine replaced by hydrophilic
aspartic acid) would by appropriate to allow sufficient flexibility for
homo-dimeric pairing of the extra-cellular NGK2D portions but
not to provoke sensitivity to proteolytic degradation. Wildtype
NKG2D after translation into the endoplasmatic reticulum is
directed to the cell surface via an uncleaved type II transmem-
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receptor by the type I transmembrane signal anchor of CD28.
Furthermore, as type I membrane proteins require also cleavable
N-terminal signals for appropriate insertion into the cell
membrane, we introduced the cleavable N-terminal signal peptide
of CD33, which is removed in the mature protein. Figure 2A
displays a scheme of the final mature fusion protein.
Transfer of chNKG2D into different T cell populations by
electroporation of mRNA
T-cell activation might be required for triggering effector
functions also in the CD45RO
pos T cell subpopulation [28],
however, induced proliferation might accelerate the loss of
chNKG2D expression due to dilution of transfected mRNA.
Thus, we compared resting and activated T cells. CD8
pos and
CD4
pos T cells were purified from peripheral blood and
electroporated either directly or 12 days after activation via
CD3, when proliferation had declined again. Figure 2B shows the
expression of chNKG2D one day after transfection. Detection was
done by an anti-NKG2D(CD314)-antibody, which also detects
endogenous NKG2D expressed in CD8
pos T cells. T cells
transfected with a CMV-gH-specific control CAR [23] were thus
included in Figure 2B for comparison. ChNKG2D-mRNA-
transfected T cells displayed strongly increased anti-NKG2D-
Figure 1. Expression of NKG2D-Ls in ESFT. The histograms show the surface expression of the respective NKG2D-Ls recognized by specific
monoclonal antibodies and analyzed by flow cytometry (filled histograms=specific antibodies; open histograms=isotype controls). The two stably
transfected murine B cell lines (Ba/F3) expressing either human MICA or ULBP2 are displayed for comparison.
doi:10.1371/journal.pone.0031210.g001
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channel numbers from three independent experiments using cells
from different donors, we calculated a 5–9-fold increased
chNKG2D expression density in chNKG2D-RNA-transfected
activated CD8
pos T cells compared to endogenous NKG2D
(Fig. 2B and data not shown). The expression of chNKG2D was
homogeneous and augmented following cell activation both in
CD4
pos and CD8
pos T cells compared to the resting cells.
NKG2D-Ls are monomeric and are recognized only by the
homo-dimerized native NKG2D receptor by asymmetric binding
of the a1- and the a2-epitopes of the ligands [16]. Here, we
evaluated the functional activity of the novel chNGK2D type.
Figure 2C shows that chNKG2D
pos T cells can induce apoptosis in
a murine cell line stably expressing the NKG2D-ligand MICA
(Fig. 1). This experiment also illustrates that resting chNKG2D
pos
T cells were clearly inferior to CD3-activated chNKG2D
pos T
cells, which killed their target cells even at an effector:target (E:T)
ratio of only 1:1. Importantly, apoptosis in MICA
pos targets was
induced both by chNKG2D-expressing CD8
pos as well as CD4
pos
T cells. The data so far confirmed that the novel recombinant
chNKG2D is functional and that RNA transfection allows high
level expression on the surface of primary T cells.
ESFT cells are killed by T cells transfected with chNKG2D
mRNA
In the following experiments we tested the capacity of RNA
transfected activated T cells to recognize ESFT cells with varying
and partially low ligand density (Fig. 1). Figure 3A illustrates the
lysis of ESFT cells by T cells expressing either chNGK2D or an
irrelevant CMV-specific control receptor. ESFT cells were
specifically lysed by chNKG2D
pos T cells. Notably, chNKG2D
pos
CD4
pos T cells lysed over 20% of ESFT cells at an E:T ratio of
only 4:1 and even targets with low-level ligand density such as
STA-ET-8.2 and -11. Figures 3B and 3C demonstrate that
chNKG2D also mediated specific cytokine release in mRNA
transfected CD4
pos T cells, as shown by detection of TNF and
soluble FasL. Together, these results confirm that chNKG2D-
RNA transfected T cells specifically recognize ESFT cells even
with low ligand density. Furthermore, the data suggest that also
the CD4
pos subset of T cells could mediate an efficient anti-ESFT
response.
Lentiviral expression of chNKG2D
For lentiviral expression we cloned chNKG2D into the
bicistronic vector pWPI, which was previously optimized for
high-level transgene expression in hematopoietic cells [29].
Transduction of PHA-activated T cells yielded expression of
chNKG2D in different cell types at similar proportions (16.1% of
chNKG2D
pos CD8
neg cells and 19.3% of chNKG2D
pos CD8
pos
cells in a representative experiment, data not shown). After
removal of PHA but in the continued presence of IL-2
chNKG2D
pos cells enriched during prolonged culture (data not
shown), suggesting an auto-stimulatory effect possibly through
endogenous expression of NKG2D-Ls induced by PHA stimula-
tion [30]. Accelerated enrichment and expansion was achieved by
restimulation with an ULBP2
pos murine Ba/F3 cell line (Fig. 4A).
Repeated restimulation in IL-2 supplemented medium resulted in
highly enriched (.80%) chNKG2D
pos CD8
pos and CD4
pos T cells
that could be expanded for at least three months. Expression of the
receptor was stable during the whole period of restimulation, and
waned only gradually over a time period of few weeks after
cessation of periodical restimulation (data not shown). Figure 4B
shows the specific TNF production of enriched chNKG2D
pos
CD4
pos T cells in response to different NKG2D-L
pos tumor cells.
Finally, we directly compared the lytic activity of CD8
pos T cells
modified with chNKG2D either by lentiviral gene transfer or by
mRNA electroporation. As shown in Figure 4C, both transfer
methods conferred lytic capacity to a comparable extent against
ULBP2 expressing target cells but not against ligand negative
control cells. Not surprisingly, we observed also weak lysis of
ULBP2
pos target cells, but not of ULBP2
neg control cells, when co-
cultured with receptor unmodified CD8
pos effector cells, which we
ascribe to endogenous expression of (costimulatory) CD314
(NKG2D).
Together the data demonstrate that lentiviral transduction
allowed ligand induced long-term proliferation and the generation
of highly enriched chNKG2D
pos T cells, which were characterized
by a strong NKG2D-L specific responsiveness comparable to that
observed with mRNA modified T cells.
Stability of chNKG2D surface expression upon target cell
recognition
Our data so far confirmed that both mRNA transfection and
lentiviral transduction mediated high level expression of the
chNKG2D in T cells. However, ligand-induced receptor inter-
nalization, which is known for T cell receptors (TCRs) and has
been reported also for CARs, could result in a significant loss of
receptor molecules from the cell surface upon target cell
recognition [31]. For this purpose, we compared the stability of
chNKG2D surface expression obtained by either RNA electropo-
ration or by lentiviral transduction, after co-culture with
MICA
pos/ULBP2
pos STA-ET-3 target cells (Fig. 5A). Co-culture
of the RNA-modified cells one day after electroporation with a 2.7
fold excess of STA-ET-3 target cells for 24 hours led to a
reduction of the surface expression of chNKG2D by more than
90% compared to the expression observed in T cells without co-
culture, as estimated by peak channel numbers (without co-
culture: 1762; with co-culture: 87). This was in contrast to
lentivirally modified T cells, in which chNKG2D expression even
slightly increased during co-culture. As the extent of CAR
internalization is strongly determined by the target antigen density
[31,32], we investigated the effect of interaction with ESFT cell
lines characterized by different levels of NKG2D-L expression.
Figure 5B illustrates that chNKG2D down-modulation in mRNA
signaling platform creating a transmembrane receptor of type I orientation in which the relative orientation and positioning of the NKG2D
ectodomain has not been changed. B, efficient transfection and strong surface expression of chNKG2D by electroporation of mRNA into primary T
cells. The histograms show the surface expression of chNKG2D 24 hours after electroporation of quiescent or anti-CD3-activated human T cells (thick
line, open histogram). Analysis was performed by flow cytometry using an anti-CD314 antibody. The expression of endogenous wildtype NKG2D in T
transfected with a CMV-gH-specific CAR is shown for comparison (thin line, open histograms; filled histograms=isotype controls). C, chNKG2D
triggers cytotoxicity of activated T cells. Quiescent or anti-CD3-activated CD8
pos or CD4
pos T cells were transfected with RNA encoding either the
chNKG2D or a CMV-gH-specific control receptor. One day after transfection, the T cells were co-cultured with dye-labeled murine B cells (Ba/F3-MICA)
stably expressing the human NKG2D-L MICA. The diagram shows the percentage of Annexin V
pos murine target cells after 5 hours of co-culture at the
indicated E:T ratios (data pooled from three independent experiments using different cell donors; mean 6 S.D.). Statistical significance was calculated
for the effects of activated T cells expressing the chNKG2D versus T cells expressing the control receptor.
doi:10.1371/journal.pone.0031210.g002
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cells.
In the following experiments we investigated the influence of the
ESFT cell line STA-ET-3, most effective in CAR down-
modulation with mRNA transfected T cells, in more detail.
Figure 5C illustrates, that the capacity of mRNA-electroporated T
cells to compensate for ligation induced chNKG2D down-
regulation strongly decreased already early after transfection.
Target-cell encounter three days after transfection almost
completely down-modulated chNKG2D from the cell surface
within only 4 hours of contact at an E:T ratio of 1:3. Finally, we
compared two differentially engineered RNA species encoding
chNKG2D for their capacity to compensate receptor down-
modulation by lower number but prolonged presence of target
cells (Fig. 5D). RNA #1 refers to the RNA used in all experiments
described above and RNA #2 was modified according to
Holtkamp et al. with RNA stabilizing elements [25]. The figure
illustrates the comparably slow decline of chNKG2D expression
Figure 3. Targeting ESFT cells by chNKG2D-mRNA transfected T cells. A, Lysis of ESFT cells. The diagram shows the lytic activity of anti-CD3-
activated CD8
pos and CD4
pos T cells transfected with mRNA encoding either chNKG2D or a similar chimeric CMV-gH-specific control receptor (aCMV-
gH-CAR) in response to ESFT cells with different ligand expression (stated in brackets). Displayed is the specific lysis of the indicated ESFT cell lines at
the indicated E:T ratio (measured by Eu-release; mean 6 S.D. of triplicates). Statistical significance was calculated for the effects of T cells expressing
the chNKG2D versus T cells expressing the control receptor where indicated. B and C, Cytokine secretion of chNKG2D-mRNA transfected CD4
pos T
cells in response to ESFT cells. The diagrams show TNF and FasL secretion by CD4
pos T cells transfected with RNA encoding chNKG2D or a CMV-gB-
specific control receptor in response to the indicated cell lines or only medium as control (measured by ELISA; mean of duplicates).
doi:10.1371/journal.pone.0031210.g003
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PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e31210Figure 4. Lentiviral transduction for transfer of chNKG2D. A, antigen-specific enrichment of lentivirally transduced chNKG2D
pos MNCs. On day
13 after transduction the cells were co-cultured either with Ba/F3, ULBP2
pos Ba/F3 or without target cells. FACS analysis was performed 6 days later
(open histogram, bold line: co-culture with the ULBP2
pos Ba/F3, 86.7% chNKG2D
pos T cells; filled histogram, dotted line: co-culture with Ba/F3, 60.7%
chNKG2D
pos T cells; thin line: cells cultured without target cells, 54.1% chNKG2D
pos T cells; open histogram, dotted line=secondary antibody only). B,
cytokine production. The diagram shows TNF secretion of purified CD4
pos T cells lentivirally transduced with either chNKG2D (enriched to 83–92%
positive cells) or a similar chimeric CMV-specific control receptor (enriched to 69–81%) in response to the indicated cell lines or only medium as
control (measured by ELISA; mean of duplicates). Ba/F3 or ULBP2
pos Ba/F3 cells were used for negative and positive control. Statistical significance
was calculated for the effects of T cells expressing the chNKG2D versus T cells expressing the control receptor. C, Comparison of the cytotoxic
response triggered by chNKG2D either stably or transiently transferred. CD8
pos T cells either unmodified (‘‘without chNKG2D’’) or expressing
chNKG2D by lentiviral transduction (‘‘LV’’; enriched for chNKG2D
pos .90%) or mRNA transfection (‘‘mRNA’’; 20 hours after electroporation) were co-
cultured with dye-labeled murine Ba/F3 cells expressing human ULBP2 (ULBP2-Ba/F3) or not (CTRL-Ba/F3). The diagram shows the percentage of
Annexin V
pos Ba/F3 target cells after 4 hours of co-culture at the indicated E:T ratios (mean 6 S.D. of triplicates).
doi:10.1371/journal.pone.0031210.g004
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PLoS ONE | www.plosone.org 8 February 2012 | Volume 7 | Issue 2 | e31210Figure 5. Stability of receptor surface expression upon target-cell encounter. The histograms show the flow cytometric analysis of
chNKG2D expression (detected in CD4
pos T cells by an anti-CD314 antibody or in CD8
pos T cells by an anti-human-IgG1-Fc antibody; log scale in all
histograms; note: amplification voltage in flow cytometric analysis was lowered for lentivirally transduced T cells due to the strong expression of the
receptor). A, comparison of lentivirally transduced and mRNA transfected T cells. 75,000 chNKG2D
pos CD4
pos T cells were cultured 24 hours after
electroporation for further 24 hours in presence or absence of 200,000 STA-ET-3 cells (filled grey histograms=presence of STA-ET-3, open histograms
bold line=absence of STA-ET-3, open histograms dotted line=T cells not transfected). Shown is one representative experiment out of three
independent repetitions. B, chNKG2D down-regulation in response to different ESFT cell lines. 100,000 chNKG2D
pos CD8
pos T cells were co-cultured
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transfection, when T cells were cultured without target cells (open
histograms, bold line). A markedly accelerated decline occurred,
when target cells were added 2 or 26 hours after transfection. The
receptor was strongly down-regulated at time point 30 hours after
transfection, when tumor cells were added 2 hours after
transfection at an E:T ratio of 1:1 (filled histograms). Addition of
tumor cells at later time points (26 hours after transfection)
resulted in more pronounced chNKG2D down-regulation at time
point 50 hours after transfection. Then, even lower amounts of
tumor cells (E:T 1:0.33; open histograms, thin line) resulted in
marked down-regulation, which after an additional day of co-
culture (FACS analysis 74 hours after transfection) was very
similar to cultures with an E:T of 1:1. Importantly, almost
identical effects were observed with both types of mRNA, although
RNA #2 slightly mitigated the ligation induced down-modulation
(visible at E:T 1:0.33). Together, these experiments had shown
that the extent of down-modulation correlates with target cell
numbers and increases with time following transfection.
It has been reported that endogenously expressed NKG2D is
down-regulated by cell-bound ligands but not by soluble ligands
[33,34]. In view of the observed reduction of chNKG2D cell
surface density in mRNA-transfected T cells, we wanted to
investigate this issue with sera from tumor patients, which are
known to frequently contain high levels of a soluble fraction of
different NKG2D-Ls and thereby could inactivate injected T cells.
Thus, we co-cultured RNA-modified CD4
pos T cells with two sera
of neuroblastoma patients containing high detectable levels of
MICA (171 and 494 pg/ml; ‘‘NB1’’ and ‘‘NB2’’ respectively). In
these experiments, however, we did not observe any reduction of
chNKG2D surface density (Fig. 5E).
Discussion
The goal of our study was to evaluate the potential of a T cell
based approach for adoptive therapy of EFST using a chimeric
NKG2D receptor and to compare the suitability of two different
methods for receptor transfer. For this aim we investigated
NKG2D-Ls, which have previously been reported to be expressed
in ESFT [4], as potential ESFT target antigens. In confirmation
and extension of Verhoeven et al.’s data, we found NKG2D-Ls
consistently expressed in all of 14 tested ESFT cell lines (Fig. 1).
Based on this and on the fact that our chNKG2D modified T cells
efficiently recognized ESFT cells also with low NKG2D-L
expression, we propose a chNKG2D based approach for
immunotherapy of ESFT lesions.
Originally, the feasibility of redirecting T cells to NKG2D-Ls
has been demonstrated by Sentman et al. using NKG2D fused as a
full-length protein to the cytoplasmic domain of CD3f [11–14].
For our study, we intended to construct a NKG2D-based CAR
with an integrated costimulatory CD28 domain for enhanced T
cell activation [8,15]. Notably, CD28 signaling enhances the
resistance to TGF-b1 and regulatory T cells (Tregs) and thus could
be particularly relevant in metastasized ESFT, for which secretion
of TGF-b1 and increased numbers of infiltrating Tregs have been
described [20,35,36]. Further, signal amplification by CD28
reduces the threshold of endocytosed receptor molecules required
for T cell activation [37], and, hence may be favorable for
targeting ESFT, which express NKG2D-Ls often at rather low
levels (Fig. 1). Low target antigen density may impair the
activation of CAR modified T cells, as CARs require about 100
fold higher target antigen densities than T cell receptors to activate
a T cell, which is explained by the lack of serial triggering due to
high affinity interaction [31,32,37,38]. Specifically, using a first
generation CAR, James et al. have shown that it requires ,30,000
target molecules/target cell (inducing endocytosis of ,20,000
CAR molecules) to trigger maximum lytic activity [31,32].
Increased ligand densities may be required if receptor expression
is low [39].
In line with these theoretical considerations we indeed found
that CD8
pos T cells redirected by our novel type of chNKG2D at
high expression levels could efficiently lyse ESFT cells even when
their ligand expression was low (e.g. STA-ET-11; Fig. 3A). This
might be important and appears to be in line with the reported
NK cell lysis of ESFT cells, for which also no relation between
susceptibility to lysis and the expression levels of the triggering
ligands has been reported [5].
Activated NK cells have been shown to kill ESFT cells with high
efficiency [4,5]. By using a flow cytometry-based method, Cho et
al. have observed up to 87% propidium iodide positive cells within
4 hours of co-culture at an E:T ratio of 1:1. In our study we relied
on a cytotoxicity-assay based on the release of non-radioactive
Europium (Fig. 3A) or flow-cytometry using Annexin V staining
(Figs. 2C and 4C). In general, the Annexin V based method seems
to give higher estimates of cytotoxicity (data not shown), probably
due to the fact that Annexin staining detects early steps of
apoptosis. Taken into account the different methods used by this
group and by us, our results with CAR modified T cells appear to
be within the same magnitude of killing efficiency compared to the
NK cells tested by Cho et al.
The cytotoxicity results shown in Figures 2C and 3A underline
that CD4
pos T cells in addition to the CD8
pos subset are attractive
candidates for expression of the chNKG2D. The observed strong
cytotoxicity of CD4
pos T cells might be explained by several
potentially cytotoxic proteins. We found that chNKG2D modified
CD4
pos T cells in response to ESFT cells did not express detectable
amounts of TRAIL or perforin (data not shown). However, we
found soluble FasL in the supernatants of these cells (Fig. 3C),
which may contribute to killing since ESFT cells are sensitive to
Fas cross-linking (data not shown and [40–42]).
Apart from chNKG2D-dependent cytotoxicity, we repeatedly
observed some chNKG2D-independent background killing by
particularly CD8
pos T cells (unmodified or expressing an irrelevant
control-CAR; Figs. 2C, 3A, and 4C) which we could not attribute
to eventually contaminating NK cells (purity of the cell population
after cell sorting and cell expansion: ,1% NK cells; data not
shown). Such CAR-independent cytotoxicity, however, may likely
be due to endogenously expressed NKG2D and other activating
50 hours after mRNA electroporation for further 24 hours with 100,000 cells of different ESFT cell lines as indicated (unmodified T cells=‘‘without
chNKG2D’’; without co-culture=‘‘without target cells’’). C, kinetics of chNKG2D down-regulation upon target-cell encounter at different times after
transfection. 20,000 chNKG2D
pos CD4
pos T cells were co-cultured with 60,000 STA-ET-3 target cells for different times (1, 4, or 48 hours) before
chNKG2D expression was determined (6, 30, or 74 hours after transfection) (one experiment). D, comparison of differentially stabilized mRNA species.
ChNKG2D
pos CD4
pos T cells were co-cultured with STA-ET-3 target cells at different effector:target ratios and at different times after transfection.
Target cells were added at the indicated ratios either two or 26 hours after transfection and chNKG2D expression was determined by flow cytometry
6, 30, 50, or 74 hours after transfection. Shown is one out of three experiments. E, effect of patient serum containing soluble NKG2D-Ls. 15,000
chNKG2D
pos CD4
pos T cells were cultured 24 hours after electroporation for further 24 hours with or without serum of two different neuroblastoma
patients (final serum concentration 33%).
doi:10.1371/journal.pone.0031210.g005
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described to mediate strong TCR-independent lysis of many
tumor cell lines [43,44]. Its ligands, CD155 and CD112, are also
frequently up-regulated in tumors including ESFT. Together with
NKG2D-Ls the ligands of DNAM-1 efficiently trigger NK cell
cytotoxicity against ESFT cells [4,21,45] and likely also mediate
some CAR-independent killing of ESFT by activated CD8
pos and
CD4
pos T cells. With regard to the background FasL production
observed also in cultures containing control-CAR transfected T
cells (Fig. 3C), we cannot exclude a contribution from the ESFT
cells themselves [46]. However, when cultured without T cells, our
ESFT cell lines produced less than 60 pg/ml sFasL (data not
shown).
For redirecting T cells we used RNA transfer and lentiviral
transduction which both allowed high level expression of
chNKG2D and comparable elimination of target cells. Regarding
the persistence of the expression, it is known that transfected
mRNA maintains substantial translation only within the first day
after electroporation [25], but that the translated protein persists at
high density on the cell surface for several days. According to our
data, the persistence on the cell surface actually might be much
more limited due to rapid ligand induced receptor internalization
upon target cell recognition. Ligand induced receptor internaliza-
tion is important for proper signal transduction [47,48], and has
been quantified for the T cell receptor complex and also for CARs
[31,37]. CARs are internalized by ligands roughly at a ratio of 1:1
whereas 100 fold more TCR molecules per target antigen are
internalized due to serial triggering.
Cross-linking of transmembrane receptors generally results in
rapid redistribution from the cell surface into intracellular
compartments, where a fraction of the receptors enters lysosomal
degradation instead of being recycled back to the cell surface
[47,48]. As a consequence, a high density of ligand molecules on
target cells can rapidly reduce the cell surface density of
retrovirally expressed CAR molecules below the critical threshold
required for T cell activation resulting in the loss of serial killing
capacity [31].
Here we show that the strong lentiviral expression of our
chNKG2D could effectively compensate ligand induced internal-
ization in response to STA-ET-3 cells, expressing several different
NKG2D-Ls (Figs. 1 and 5A), whereas mRNA transfection was
similarly effective only during the first hours after electroporation
(Fig. 5D). Target cell contact at later time points, however,
resulted in strong and irreversible down-modulation of chNKG2D
(Figs. 5C and 5D). Notably, this was seen with mRNA, for which
we had applied state of the art techniques to maximize stability
and translation, i.e. extensive polyadenylation and capping with a
specially modified cap analog (see materials and methods) [25,49].
Further attempts to improve mRNA stability according to
Holtkamp et al. yielded only negligible effects (‘‘RNA #2’’ in
Fig. 5D) [25,49].
Such characteristics of mRNA mediated CAR expression could
be significant, since clinical studies have shown, that intravenously
administered T cells in humans due to extensive organ trapping
and long migration distances reach tumor sites only two or three
days after infusion [50,51]. Our observations would argue for
injecting mRNA transfected T cells in humans not only
repetitively but also perhaps intra-tumorally or intra-arterially to
ensure that the T cells meet their targets without any further delay.
Regardless of the applied receptor transfer strategy, our data
illustrate for the first time the potential of an NKG2D based
approach for targeting ESFT cells by receptor modified T cells.
The new receptor efficiently triggered the elimination of ESFT
cells in vitro by CD8
pos and CD4
pos T cells and thereby opens a
new avenue for developing an adoptive T cell approach that could
have the potential to complement conventional multimodal
therapy of ESFT.
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